Moderna seeks US approval for 94.1% effective vaccine

US News

Moderna has said it is filing for regulatory approval in the US, and that its vaccine trials have shown no serious safety concerns.

The US-based company has also said its vaccine was 94.1% effective, with 100% efficacy against severe COVID-19 in its phase three trial.

Efficacy was consistent across age, race and ethnicity, as well as gender, the company has said.

Speaking to Reuters news agency, chief medical officer Dr Tal Zaks said: “We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it.”

Products You May Like

Articles You May Like

PM leads politicians’ tributes to Prince Philip’s lifelong ‘ethic of service’
Bad Bunny Shocks WWE Crowd in Impressive WrestleMania Debut
CupcakKe Shares Video for New Song “Mickey”: Watch
Here’s who just got rich from the Coinbase debut
Senators push for reopening of international travel, lift of CDC’s sailing ban for cruise lines

Leave a Reply

Your email address will not be published. Required fields are marked *